Oncolytics Biotech, Inc. (TSE:ONC)’s share price hit a new 52-week low on Wednesday . The company traded as low as C$2.20 and last traded at C$2.22, with a volume of 20914 shares. The stock had previously closed at C$2.27.

Separately, Royal Bank of Canada dropped their target price on shares of Oncolytics Biotech from C$10.00 to C$9.00 and set an “outperform” rating for the company in a research note on Tuesday, May 7th.

The company has a market capitalization of $46.28 million and a price-to-earnings ratio of -2.16. The company has a current ratio of 3.39, a quick ratio of 3.14 and a debt-to-equity ratio of 13.67.

Oncolytics Biotech (TSE:ONC) last announced its earnings results on Friday, March 8th. The company reported C($0.28) earnings per share for the quarter. On average, equities analysts predict that Oncolytics Biotech, Inc. will post -0.769999996652174 EPS for the current fiscal year.

WARNING: This news story was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this news story on another site, it was stolen and republished in violation of US and international trademark and copyright law. The legal version of this news story can be viewed at https://www.thecerbatgem.com/2019/05/22/oncolytics-biotech-onc-hits-new-52-week-low-at-2-20.html.

Oncolytics Biotech Company Profile (TSE:ONC)

Oncolytics Biotech Inc, a development stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing REOLYSIN, an immuno-oncology viral-agent that comprises three programs: chemotherapy combinations to trigger selective tumor lysis; immune modulator combinations to facilitate innate immune responses; and immuno-therapy combinations to produce adaptive immune responses.

Featured Story: Dividend

Receive News & Ratings for Oncolytics Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncolytics Biotech and related companies with MarketBeat.com's FREE daily email newsletter.